End-stage renal disease is a devastating condition that, according to the United States Renal Data System, plagued approximately 406,000 individuals in the United States in 2001 and is projected to increase to a prevalence of approximately 725,000 by 2010. Furthermore, it is a major public health issue, given the overall poor outcomes and high costs for this chronic condition.
When it comes to treating lipids in patients with heart disease, the mantra may be, The lower the LDL, the better. Data from the multicenter Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial indicate that aggressive reduction of atherogenic lipoproteins prevents progression of disease.
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
Physicians increasingly are aware of the need to provide prophylaxis against venous thrombosis for the medically ill patient in the hospital environment. This article attempts to separate the fact from fiction regarding VTE prophylaxis.
Breast Cancer and the Use of Statins; Warnings Issued for IBS Drugs; FDA Actions
The NIH has halted the estrogen-alone wing of the Womens Health Initiative a year before its scheduled end.
